# Xilio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xilio-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.xiliotx.com
- Total disclosed funding: $233M
- Latest round: Series C (Feb 23, 2021)
- Investors on record: 14

## About

Established in 2016 and based in Massachusetts, US, Xilio Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapeutic products and tumor-selective therapies that overcome toxicities associated with validated IO therapies. The company was founded by Rene Russo (CEO). In February 2021, Xilio Therapeutics raised USD 95 million in series C funding from Atlas Venture, Bain Capital Life Sciences, Deerfield Management, MRL Ventures Fund, RA Capital Management, RiverVest Ventures, Rock Springs Capital, SV Health Investors, and Takeda Ventures. In October 2021, the company got listed on Nasdaq Global Select Market under the ticker symbol XLO.

Xilio Therapeutics focuses on enhancing the lives of cancer patients by utilizing the immune system to create deep and long-lasting clinical responses. The company's line of products includes XTX202 (Tumor-selective IL-2 agonist), XTX301 (Tumor-selective IL-12), XTX401 (Tumor-selective IL-15), and XTX101 (Tumor-selective anti-CTLA-4 antibody).

Xilio Therapeutics, Inc. plans to use the funds to advance XTX202 and XTX101 into clinical development.

## Funding rounds

- Series C, Feb 23, 2021, $95M — Atlas Venture, Bain Capital, RiverVest Ventures Partners, SV Health Investors, Takeda Ventures, Deerfield Management, RA Capital Management, Rock Springs Capital, MRL Ventures Fund
- Series B, Jun 18, 2020, $101M — Atlas Venture, RiverVest Ventures Partners, SV Health Investors, Bay City Capital, F-Prime Capital, Ipsen, Takeda Ventures, M Ventures, MRL Ventures Fund, Solasta Ventures
- Series A, Sep 27, 2018, $30M — Atlas Venture, F-Prime Capital
- Series A, Oct 12, 2016, $7.5M — F-Prime Capital

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B, Series C
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B
- Ipsen — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B, Series C
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series B, Series C
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C